AgomAb Therapeutics

Franklin Rooseveltlaan 348 126

9000 Gent

BE

AgomAb Therapeutics

Foundation date

13/04/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

AgomAb is developing molecular therapies for the regeneration of damaged tissues. Our unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.

Upcoming events

Latest news

  • Tom Plitz commences role as Chief Executive Officer of Precirix

    Friday March 1st 2024

  • Newly discovered protein blocks sleeping sickness

    Wednesday February 28th 2024

  • DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

    Wednesday February 28th 2024